One-Sample Multiple Testing Procedure for Phase II Clinical Trials
From MaRDI portal
Publication:3938400
DOI10.2307/2530297zbMath0479.62083OpenAlexW1984254136WikidataQ70365924 ScholiaQ70365924MaRDI QIDQ3938400
Publication date: 1982
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2530297
Nonparametric hypothesis testing (62G10) Applications of statistics to biology and medical sciences; meta analysis (62P10)
Related Items
Determination of the optimal sample size for a clinical trial accounting for the population size, SEQUENTIAL METHODS IN CLINICAL TRIALS*, Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses, Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm, Optimal group sequential tests with groups of random size, Exact confidence limits for the probability of response in two-stage designs, Stopping for efficacy in single-arm phase II clinical trials, Methodology and application of adaptive and sequential approaches in contemporary clinical trials, A class of confidence intervals for sequential phase II clinical trials with binary outcome, On the maximum total sample size of a group sequential test about binomial proportions., Improving the Flexibility and Efficiency of Phase II Designs for Oncology Trials, Group sequential comparison of two binomial proportions under ranked set sampling design, On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions, Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes, Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology, Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials, Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity, Exact confidence limits compatible with the result of a sequential trial, A review of phase 2-3 clinical trial designs, Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach, MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
